Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib
Cholangiocarcinoma (CCA) remains an aggressive malignancy characterized by late-stage diagnosis, substantial molecular heterogeneity, and limited therapeutic options. Advances in molecular characterization have identified actionable alterations and expanded systemic treatment beyond conventional cytotoxic chemotherapy....